Caxton Corporation’s Xeris Biopharma Holdings XERS Stock Holding History

Caxton Corporation’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,015,157	Closed	-$6.83M	–	15
2024 Q4	$6.83M	Sell	2,015,157 -3,098,191	-61%	-$9.97M	41.06%	1
2024 Q3	$14.6M	Hold	5,113,348	–	–	60.31%	1
2024 Q2	$11.5M	Hold	5,113,348	–	–	58.31%	1
2024 Q1	$11.3M	Sell	5,113,348 -528,572	-9%	-$1.37M	64.38%	1
2023 Q4	$13.3M	Hold	5,641,920	–	–	71.57%	1
2023 Q3	$10.5M	Hold	5,641,920	–	–	39.87%	2
2023 Q2	$14.8M	Sell	5,641,920 -397,108	-7%	-$1.01M	42.66%	2
2023 Q1	$9.84M	Hold	6,039,028	–	–	24.86%	2
2022 Q4	$8.03M	Hold	6,039,028	–	–	20.52%	2
2022 Q3	$9.42M	Hold	6,039,028	–	–	17.72%	3
2022 Q2	$9.3M	Hold	6,039,028	–	–	12.49%	3
2022 Q1	$15.5M	Sell	6,039,028 -271,518	-4%	-$663K	19.22%	1
2021 Q4	$18.5M	Buy	+6,310,546	New	+$13.6M	15.11%	1

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Caxton Corporation's XERS Position: Q1 2025 in Review

Caxton Corporation sold out of Xeris Biopharma Holdings (XERS) in Q1 2025, closing a stake of 2,015,157 shares — an estimated $6.83M sold.

Caxton Corporation first reported a position in XERS in Q4 2021 and held it in 13 quarters. The position peaked at $18.5M in Q4 2021. 199 funds tracked by Wall St. Rank hold XERS as of Q1 2025.

Caxton Corporation reported no remaining Xeris Biopharma Holdings position as of Q1 2025 after selling out during the quarter.
Caxton Corporation sold 2,015,157 Xeris Biopharma Holdings shares in Q1 2025, an estimated $6.83M.
Caxton Corporation first reported a position in Xeris Biopharma Holdings in Q4 2021 and held it in 13 quarters.
Caxton Corporation's Xeris Biopharma Holdings position peaked at $18.5M in Q4 2021.
199 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2025.

Based on Caxton Corporation's 13F filing for Q1 2025, filed 15 May 2025.